Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Sells $16,170.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Dipal Doshi sold 1,000 shares of the firm’s stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $16.17, for a total value of $16,170.00. Following the completion of the sale, the chief executive officer now directly owns 336,375 shares of the company’s stock, valued at $5,439,183.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Dipal Doshi also recently made the following trade(s):

• On Thursday, May 16th, Dipal Doshi sold 1,800 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.00, for a total value of $27,000.00.

Entrada Therapeutics Stock Performance

NASDAQ:TRDA opened at $15.78 on Monday. The business’s fifty day moving average is $14.21 and its 200 day moving average is $14.24. The firm has a market cap of $532.73 million, a price-to-earnings ratio of 25.05 and a beta of -0.23. Entrada Therapeutics, Inc. has a 52-week low of $10.75 and a 52-week high of $18.44.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of ($0.38) by $1.06. Entrada Therapeutics had a return on equity of 9.73% and a net margin of 14.42%. The firm had revenue of $59.12 million for the quarter, compared to analysts’ expectations of $25.00 million. Equities analysts predict that Entrada Therapeutics, Inc. will post -0.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Entrada Therapeutics in a report on Monday, March 18th.

Institutional Trading of Entrada Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP raised its position in shares of Entrada Therapeutics by 2.6% in the third quarter. Wellington Management Group LLP now owns 1,045,652 shares of the company’s stock worth $16,521,000 after buying an additional 26,144 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Entrada Therapeutics by 27.7% in the 4th quarter. SG Americas Securities LLC now owns 11,714 shares of the company’s stock valued at $177,000 after acquiring an additional 2,540 shares in the last quarter. Strs Ohio boosted its position in shares of Entrada Therapeutics by 792.6% during the 4th quarter. Strs Ohio now owns 24,100 shares of the company’s stock valued at $363,000 after acquiring an additional 21,400 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Entrada Therapeutics by 476.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,780 shares of the company’s stock valued at $87,000 after acquiring an additional 4,777 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Entrada Therapeutics by 427.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after purchasing an additional 11,965 shares during the last quarter. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.